FDA approves daraxonrasib for pancreatic cancer
Analysis based on 92 articles · First reported Aug 26, 2026 · Last updated Aug 29, 2026
The approval is expected to drive significant revenue for Revolution Medicines, with analysts estimating $28 million in Q3 2026 U.S. sales and $148 million in Q4, and potential annual sales of $11.5 billion. The stock has already risen 166% this year on expectations, and the approval reinforces investor confidence in RAS-targeting therapies, potentially boosting the broader oncology biotech sector.
On August 26, 2026, the U.S. United States — Food and Drug Administration granted expedited approval to daraxonrasib, a first-in-class oral RAS inhibitor developed by Revolution Medicines and marketed as Rasonque, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are ineligible for multiagent chemotherapy. The approval was based on the Phase 3 RASolute 302 trial, which showed a median overall survival of 13.2 months for daraxonrasib versus 6.7 months for chemotherapy, a 60% reduction in risk of death, and a doubling of progression-free survival. The drug targets multiple RAS isoforms, including KRAS mutations present in over 90% of pancreatic cancers, a target previously considered 'undruggable.' The FDA approved the drug 6.5 months ahead of its user-fee deadline, under Breakthrough Therapy, Orphan Drug, and Priority Review designations, and the Commissioner's National Priority Voucher pilot program. Revolution Medicines set a wholesale acquisition cost of $39,800 for a 30-day supply. The approval was hailed by oncologists as a landmark advance, with more than 2,000 patients already enrolled in an expanded access program. The drug is also under rolling review by the European Union — European Medicines Agency. Revolution Medicines is studying the technology in other RAS-driven cancers, including lung cancer.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard